Search research articles
Contact Us
Filters
Showing results (201-210 of 248) with videos related to
Page
of 25
Sort By:
Biorxiv : the Preprint Server for Biology
|
October 31, 2023
Skeletal muscle BMAL1 is necessary for transcriptional adaptation of local and peripheral tissues in response to endurance exercise training
Mark R Viggars, Hannah E Berko, Stuart J Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
Paul J Hesketh, Kari Bohlke, Gary H Lyman, et al.
The Annals of Thoracic Surgery
|
July 26, 2015
Surgical Outcomes in a Large, Clinical, Low-Dose Computed Tomographic Lung Cancer Screening Program
Bryan L Walker, Christina Williamson, Shawn M Regis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1994
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
P J Hesketh, W H Harvey, W G Harker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials
David G Warr, Steven M Grunberg, Richard J Gralla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1992
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting
T M Beck, P J Hesketh, S Madajewicz, et al.
Cancer
|
March 15, 1997
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group
E B Rubenstein, R J Gralla, J D Hainsworth, et al.
The Cancer Journal From Scientific American
|
January 1, 1997
Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group
T H Grote, L F Pineda, R A Figlin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 16, 2015
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies
Haralambos Raftopoulos, Abderrahmane Laadem, Paul J Hesketh, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 8, 2000
Paclitaxel and concurrent radiation for gastric cancer
H Safran, H J Wanebo, P J Hesketh, et al.
Page
of 25
Search research articles
Search
Showing results (201-210 of 248) with videos related to
Sort By:
Page
of 25
Biorxiv : the Preprint Server for Biology
|
October 31, 2023
Skeletal muscle BMAL1 is necessary for transcriptional adaptation of local and peripheral tissues in response to endurance exercise training
Mark R Viggars, Hannah E Berko, Stuart J Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
Paul J Hesketh, Kari Bohlke, Gary H Lyman, et al.
The Annals of Thoracic Surgery
|
July 26, 2015
Surgical Outcomes in a Large, Clinical, Low-Dose Computed Tomographic Lung Cancer Screening Program
Bryan L Walker, Christina Williamson, Shawn M Regis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1994
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
P J Hesketh, W H Harvey, W G Harker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials
David G Warr, Steven M Grunberg, Richard J Gralla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1992
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting
T M Beck, P J Hesketh, S Madajewicz, et al.
Cancer
|
March 15, 1997
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group
E B Rubenstein, R J Gralla, J D Hainsworth, et al.
The Cancer Journal From Scientific American
|
January 1, 1997
Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group
T H Grote, L F Pineda, R A Figlin, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
September 16, 2015
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies
Haralambos Raftopoulos, Abderrahmane Laadem, Paul J Hesketh, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 8, 2000
Paclitaxel and concurrent radiation for gastric cancer
H Safran, H J Wanebo, P J Hesketh, et al.
Page
of 25